elacestrant 345 MG Oral Tablet [Orserdu]
- RxCUI
- 2628489
- RxNorm name
- elacestrant 345 MG Oral Tablet [Orserdu]
- Display name
- elacestrant 345 MG Oral Tablet [Orserdu]
- Full name
- elacestrant 345 MG Oral Tablet [Orserdu]
- Term type
- SBD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:14
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ORSERDU | ELACESTRANT | Stemline Therapeutics, Inc. | aa66ae5c-2bd2-4444-8178-b55651e054ef | 2026-06-24 | Warnings, Adverse reactions | 2628489 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| aa66ae5c-2bd2-4444-8178-b55651e054ef | elacestrant 345 MG Oral Tablet [Orserdu] | SBD | 5 | These highlights do not include all the information needed to use ORSERDU safely and effectively. See full prescribing information for ORSERDU. ORSERDU™ (elacestrant) tablets, for oral use Initial U.S. Approval: 2023 | 20240802 |
| aa66ae5c-2bd2-4444-8178-b55651e054ef | Orserdu 345 MG Oral Tablet | PSN | 5 | These highlights do not include all the information needed to use ORSERDU safely and effectively. See full prescribing information for ORSERDU. ORSERDU™ (elacestrant) tablets, for oral use Initial U.S. Approval: 2023 | 20240802 |
| aa66ae5c-2bd2-4444-8178-b55651e054ef | Orserdu 345 MG Oral Tablet | SY | 5 | These highlights do not include all the information needed to use ORSERDU safely and effectively. See full prescribing information for ORSERDU. ORSERDU™ (elacestrant) tablets, for oral use Initial U.S. Approval: 2023 | 20240802 |